套細胞淋巴瘤市場－全球產業規模、佔有率、趨勢、機會和預測：按診斷、治療、最終用戶、地區和競爭格局分類，2021-2031年

全球套細胞淋巴瘤市場預計將從 2025 年的 27.1 億美元成長到 2031 年的 42.8 億美元，複合年成長率為 7.91%。

這種罕見且侵襲性強的B細胞惡性腫瘤，以細胞週期蛋白D1過度表達為特徵，由於人口老化導致血液系統癌症發病率上升，以及靶向口服藥物和免疫療法的監管成功，對治療的需求日益成長。這些結構性因素為該行業的長期成長奠定了堅實的基礎，使其區別於暫時的市場趨勢和處方模式的變化。

然而，該領域面臨著許多挑戰，其中最主要的障礙是先進治療方法實施成本高昂，這限制了患者的廣泛接受度和醫療覆蓋範圍。這種經濟負擔給醫療系統帶來了巨大壓力，並阻礙了在成本敏感地區的市場滲透。為了說明疾病負擔的嚴重程度，美國癌症協會估計，到2025年，美國將新增約80,350例非何傑金氏淋巴瘤病例，其中套細胞淋巴瘤是該疾病中一個尤為重要且進行性的亞型。

市場促進因素

新型標靶治療，尤其是布魯頓蛋白酪氨酸激酶抑制劑的快速核准，極大地推動了市場成長，使治療模式擺脫了傳統的細胞毒性化學療法。臨床試驗也支持了這一轉變，這些試驗表明，無論是在一線治療還是復發治療中，這些藥物都具有良好的安全性和無惡化生存期。例如，2024年6月，Astra Zeneca報告稱，在ECHO試驗中，與標準治療相比，acalabrutinib可將疾病進展或死亡風險降低27%，這鼓勵醫療機構在治療早期階段就採用這些高成本的口服療法。

同時，CAR-T細胞療法和免疫療法的推廣應用，滿足了其他治療方法無效的難治性疾病患者的迫切需求。這些突破性的生物治療方法有望實現持久緩解，並憑藉其高報銷潛力維持市場價值。根據吉利德科學公司2024年第三季財報，其細胞療法Tecartus的銷售額達到9,800萬美元，顯示儘管患者群體有限，但該療法仍獲得了顯著的市場認可。淋巴瘤研究基金會在2024年指出，這部分患者族群約佔所有非何傑金氏淋巴瘤病例的6%。

市場挑戰

全球套細胞淋巴瘤市場面臨的主要障礙是新型治療方法的高昂費用。 CAR-T細胞療法和長效口服激酶抑制劑等先進療法的定價往往超出公共和私人醫療保險機構的預算上限。這種經濟負擔迫使政府實施嚴格的用藥管理和報銷標準，這直接限制了患者獲得治療的機會，並抑制了對成本敏感地區的收入成長。

這種疾病的罕見性進一步加劇了經濟摩擦。為了從有限的患者群體中收回研發成本，製造商被迫對每位患者收取高昂的費用。有限的潛在市場規模使得該行業極易受到進入限制的影響。根據美國血液學會 (ASH) 的報告，預計到 2025 年，美國套細胞淋巴瘤的年發生率將達到約 3,589 例。如此小的患者群體，加上高昂的治療費用，使得必須採取選擇性用藥策略，從而阻礙了創新治療方法的商業性規模。

市場趨勢

非共用BTK抑制劑的廣泛應用正在逐步填補共用抑制劑抗藥性機製造成的治療空白。尤其對於第一線標準治療後病情進展的患者，新型療法如吡布替尼（pirtobrutinib）利用其可逆結合模式，即使在攜帶使傳統不可逆抑製劑失效的突變的腫瘤中，也能有效恢復疾病控制。這種臨床效用推動了其顯著的市場成長。 2024年10月，禮來公司公佈其非共用抑制劑J-Pirca第三季銷售額達8,100萬美元，反映出該藥物已迅速被納入復發病例的治療通訊協定中。

同時，雙特異性抗體的出現正在顛覆性創新，它們提供了快速、即用型的免疫療法選擇，其療效可與細胞療法相媲美。這些藥物避免了自體CAR-T細胞的生產延遲和物流複雜性，並能活化內源性T細胞直接靶向腫瘤抗原，因此非常適合疾病快速進展的患者。為了佐證此方法的高效性，OncLive在2024年12月報道，在2024年美國血液學會（ASH）年會上公佈的研究結果顯示，glofitamab單藥治療在復發/難治性患者中取得了82%的總緩解率。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球套細胞淋巴瘤市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 透過診斷（臨床檢查、影像檢查、骨髓切片檢查、其他）
  • 依治療類型（診斷{影像檢查、手術檢查、其他}，治療{化療、標靶治療、免疫療法、幹細胞移植、其他}）
  • 按最終使用者（醫院/診所、門診護理中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美套細胞淋巴瘤市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲套細胞淋巴瘤市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區套細胞淋巴瘤市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲套細胞淋巴瘤市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲套細胞淋巴瘤市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球套細胞淋巴瘤市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Gilead Sciences, Inc.
• F. Hoffman La Roche Ltd
• Abbvie, Inc.
• Celgene Corporation
• Eli Lilly and Company
• Amgen, Inc.
• Takeda Pharmaceutical Co. Ltd
• AstraZeneca Plc
• Johnson and Johnson Services Inc.
• BeiGene GmBH

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Mantle Cell Lymphoma Market is projected to expand from USD 2.71 Billion in 2025 to USD 4.28 Billion by 2031, registering a CAGR of 7.91%. This rare and aggressive B-cell malignancy, marked by cyclin D1 overexpression, is seeing increased demand for therapeutics due to the rising prevalence of hematologic cancers in aging populations and the regulatory success of targeted oral drugs and immunotherapies. These structural drivers provide a solid foundation for long-term industry growth that remains distinct from fleeting market trends or temporary prescribing shifts.

However, the sector faces significant obstacles regarding the high acquisition costs of advanced treatments, which limit widespread patient access and reimbursement coverage. This financial strain places severe pressure on healthcare systems and restricts market penetration in cost-sensitive regions. To illustrate the scale of the disease burden, the American Cancer Society estimated that approximately 80,350 new cases of non-Hodgkin lymphoma would occur in the United States in 2025, with Mantle Cell Lymphoma representing a critical and aggressive subset of this total.

Market Driver

The rapid approval of novel targeted therapies, particularly Bruton tyrosine kinase inhibitors, serves as a primary catalyst for market growth by shifting the treatment paradigm away from traditional cytotoxic chemotherapy. This transition is supported by clinical trials demonstrating superior safety and progression-free survival in both frontline and relapsed settings. For example, AstraZeneca reported in June 2024 that the ECHO trial showed acalabrutinib reduced the risk of disease progression or death by 27% compared to standard care, encouraging healthcare providers to adopt these premium-priced oral therapies earlier in the treatment continuum.

Simultaneously, the growing adoption of CAR-T cell therapies and immunotherapies is addressing high unmet needs for patients with refractory disease who have exhausted other options. These distinct biological treatments offer durable remission possibilities, sustaining market value through their high reimbursement potential. According to Gilead Sciences' third-quarter 2024 financial results, sales of the cell therapy Tecartus totaled $98 million, highlighting significant adoption despite the niche patient population, which the Lymphoma Research Foundation noted in 2024 accounts for roughly 6% of all non-Hodgkin lymphoma cases.

Market Challenge

The primary barrier hampering the Global Mantle Cell Lymphoma Market is the prohibitive cost associated with novel therapeutic modalities. Advanced treatments, such as CAR-T cell therapies and continuous oral kinase inhibitors, carry substantial price tags that frequently exceed the budgetary limits of public and private payers. This financial toxicity necessitates strict utilization management and rigorous reimbursement criteria, which directly restricts patient access to these potentially life-extending regimens and dampens overall revenue expansion in cost-sensitive regions.

This economic friction is further intensified by the orphan nature of the disease, which compels manufacturers to maintain high per-patient pricing to recover development costs from a limited population. The constrained volume of the target market makes the industry highly sensitive to access limitations. As reported by the American Society of Hematology, the annual incidence of Mantle Cell Lymphoma in the United States was projected to reach approximately 3,589 cases in 2025. This small patient pool, coupled with high treatment costs, forces a selective approach to prescribing that impedes the broader commercial trajectory of innovative therapies.

Market Trends

The widespread adoption of non-covalent BTK inhibitors is systematically addressing the therapeutic void left by covalent resistance mechanisms, particularly for patients whose disease progresses on standard frontline agents. By utilizing a reversible binding mode, novel therapies such as pirtobrutinib effectively re-establish disease control in tumors harboring mutations that render traditional irreversible inhibitors ineffective. This clinical utility is driving substantial market traction; Eli Lilly reported in October 2024 that third-quarter revenue for the non-covalent inhibitor Jaypirca reached $81 million, reflecting its rapid integration into treatment protocols for relapsed cases.

Concurrently, the emergence of bispecific antibodies acts as a disruptive force by providing immediate, off-the-shelf immunotherapeutic options that rival the efficacy of cell-based therapies. These agents bypass the manufacturing delays and logistical complexities of autologous CAR-T cells by engaging endogenous T-cells to directly target tumor antigens, making them highly suitable for patients with rapidly progressing disease. Underscoring the high efficacy of this approach, OncLive reported in December 2024 that study results presented at the 2024 ASH Annual Meeting demonstrated that glofitamab monotherapy elicited an overall response rate of 82% in the relapsed/refractory setting.

Key Market Players

• Gilead Sciences, Inc.
• F. Hoffman La Roche Ltd
• Abbvie, Inc.
• Celgene Corporation
• Eli Lilly and Company
• Amgen, Inc.
• Takeda Pharmaceutical Co. Ltd
• AstraZeneca Plc
• Johnson and Johnson Services Inc.
• BeiGene GmBH

Report Scope

In this report, the Global Mantle Cell Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mantle Cell Lymphoma Market, By Diagnosis

• Laboratory exams
• Imaging Tests
• Bone marrow Biopsy
• Others

Mantle Cell Lymphoma Market, By Treatment

• Diagnosis {Imaging Tests, Surgical Examination, Others}
• Therapy {Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others}

Mantle Cell Lymphoma Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Mantle Cell Lymphoma Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mantle Cell Lymphoma Market.

Available Customizations:

Global Mantle Cell Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Mantle Cell Lymphoma Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Laboratory exams, Imaging Tests, Bone marrow Biopsy, Others)
  • 5.2.2. By Treatment (Diagnosis {Imaging Tests, Surgical Examination, Others}, Therapy{Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Mantle Cell Lymphoma Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Mantle Cell Lymphoma Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Mantle Cell Lymphoma Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Mantle Cell Lymphoma Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End User

7. Europe Mantle Cell Lymphoma Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Mantle Cell Lymphoma Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. France Mantle Cell Lymphoma Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Mantle Cell Lymphoma Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Mantle Cell Lymphoma Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Mantle Cell Lymphoma Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End User

8. Asia Pacific Mantle Cell Lymphoma Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Mantle Cell Lymphoma Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. India Mantle Cell Lymphoma Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Mantle Cell Lymphoma Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Mantle Cell Lymphoma Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Mantle Cell Lymphoma Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End User

9. Middle East & Africa Mantle Cell Lymphoma Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Mantle Cell Lymphoma Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Mantle Cell Lymphoma Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Mantle Cell Lymphoma Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End User

10. South America Mantle Cell Lymphoma Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Treatment
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Mantle Cell Lymphoma Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Mantle Cell Lymphoma Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Mantle Cell Lymphoma Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Mantle Cell Lymphoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Gilead Sciences, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffman La Roche Ltd
• 15.3. Abbvie, Inc.
• 15.4. Celgene Corporation
• 15.5. Eli Lilly and Company
• 15.6. Amgen, Inc.
• 15.7. Takeda Pharmaceutical Co. Ltd
• 15.8. AstraZeneca Plc
• 15.9. Johnson and Johnson Services Inc.
• 15.10. BeiGene GmBH

16. Strategic Recommendations

17. About Us & Disclaimer